Robins' I.V. formulation of metoclopramide lost exclusive labeling for chemotherapy- and cisplatin-induced emesis and diabetic gastroparesis on Sept. 24, 1986. "The Pink Sheet" (Oct. 20, "In Brief") erroneously said exclusivity for the indications did not expire until December 1987. Robins did, however, recently obtain a patent covering the method of controlling emesis caused by cisplatin and cancer chemotherapy. That patent, which expires in August 2002, is the only patent in force on Reglan.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.